Résumé
While indicated for schizophrenia and acute mania, ziprasidone's evidence base and use in clinical practice extends beyond these regulatory approvals. We, an invited panel of experts led by a working group of 3, critically examined the evidence and our collective experience regarding the effectiveness, tolerability and safety of ziprasidone across its clinical uses. There was no opportunity for manufacturer input into the content of the review. As anticipated, ziprasidone was found to be effective for its indicated uses, although its utility in mania and mixed states lacked comparative data. Beyond these uses, the available data were either unimpressive or were lacking. An attractive characteristic is its neutral effect on weight thereby providing patients with a non-obesogenic long-term treatment option. Key challenges in practice include the need for dosing on a full stomach and managing its early onset adverse effect of restlessness. Addressing these issues are critical to its long-term success.
| Langue d'origine | English |
|---|---|
| Numéro d'article | 1 |
| Journal | Annals of General Psychiatry |
| Volume | 12 |
| Numéro de publication | 1 |
| DOI | |
| Statut de publication | Published - janv. 24 2013 |
Note bibliographique
Funding Information:Dr. Ashok Malla has received grant support from Astra Zeneca, Pfizer, BMS and Janssen Ortho. He has been involved with the advisory board and acted as speaker honoraria for Janssen, BMS, Pfizer, Astra-Zeneca, Sunovion, Lundbeck, and Wyeth. Dr. Heather Milliken has been involved as a speaker, member of advisory board, clinical trals and/or educational grants for Janssen-Ortho, Lundbeck, Otsuka, Pfizer, Roche, Sunovion Dr. Claire O’Donovan has received Research Funding from Elan Pharma, Pfizer, Cephalon, Brain Cells Inc. She has also been involved with the advisory boards for Astra Zeneca, Pfizer, BMS, Sunovion, Lundbeck, and Servier. Dr. Ayal Schaffer has been involed with the advisory board and speaker’s bureau for and has received research grants from AstraZeneca, BMS, Canadian Network for Mood and Anxiety Treatments, Eli Lilly, Lundbeck, and Pfizer. Dr. VH Taylor has been a speaker for Lilly, Pfizer, Lundbeck, BMS and Allergan and has received grant funding from BMS. Dr. Richard Williams has received research, ad boards, and travel support from Pfizer, Janssen-Ortho, Roche, Mylan, Lundbeck, and BMS.
Funding Information:
A panel of twelve psychiatrists and two pharmacists with relevant antipsychotic related research and clinical expertise were convened on April 16, 2010 in order to discuss and synthesize suggestions for the clinical use of ziprasidone based on current research and clinical experiences. Funding was obtained as an unrestricted grant from Pfizer Canada’s community investment funding opportunity [5]. DG and SK served as the co-chairs for the meeting and AM led the development of the manuscript. At no time did the manufacturer or any of its representatives have any input into the manuscript. There were no representatives present during the meeting proceedings and they were not privy to the content of any version of the manuscript. Psychiatrists involved
Funding Information:
This consensus project was supported by a grant from Pfizer Canada who is the manufacturer of ziprasidone. Other than providing funding for the consensus review Pfizer had no involvement in the project. No employee of Pfizer saw any content of the manuscript prior to its publications. We would like to thank Dave Carter of Multidimensional Healthcare as well as Christina Clark and Kathryn Landry for their logistical and research support throughout the project.
ASJC Scopus Subject Areas
- Psychiatry and Mental health
ODD de l’ONU
Cette action contribue à la réalisation des objectifs de développement durable suivants
